Literature DB >> 21723893

Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates.

Jason Park1, Thomas Mattessich, Steven M Jay, Atu Agawu, W Mark Saltzman, Tarek M Fahmy.   

Abstract

Biodegradable polymeric nanoparticles are widely recognized as efficacious drug delivery vehicles, yet the rational engineering of nanoparticle surfaces in order to improve biodistribution, reduce clearance, and/or improve targeting remains a significant challenge. We have previously demonstrated that an amphiphilic conjugate of avidin and palmitic acid can be used to modify poly(lactic-co-glycolic acid) (PLGA) particle surfaces to display functional avidin groups, allowing for the facile attachment of biotinylated ligands for targeting or steric stabilization. Here, we hypothesized that the incorporation, density, and stability of surface-presented avidin could be modulated through varying the lipophilicity of its fatty acid conjugate partner. We tested this hypothesis by generating a set of novel conjugates incorporating avidin and common fatty acids. We found that conjugation to linoleic acid resulted in a ~60% increase in the incorporation of avidin on the nanoparticle surface compared to avidin-palmitic acid, which exhibited the highest avidin incorporation in previous studies. Further, the linoleic acid-avidin conjugate yielded nanoparticles with enhanced ability to bind biotinylated ligands compared to the previous method; nanoparticles modified with avidin-linoleic acid bound ~170% more biotin-HRP than those made with avidin-palmitic acid and ~1300% more than particles made without conjugated avidin. Most critically, increased ligand density on anti-CD4-targeted nanoparticles formulated with the linoleic acid-avidin conjugate resulted in a 5% increase in binding of CD4(+) T cells. Thus we conclude that the novel avidin-linoleic acid conjugate facilitates enhanced ligand density on PLGA nanoparticles, resulting in functional enhancement of cellular targeting.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723893      PMCID: PMC3800156          DOI: 10.1016/j.jconrel.2011.06.025

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  36 in total

1.  Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes.

Authors:  Y Sykulev; A Brunmark; M Jackson; R J Cohen; P A Peterson; H N Eisen
Journal:  Immunity       Date:  1994-04       Impact factor: 31.745

2.  T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity.

Authors:  M Corr; A E Slanetz; L F Boyd; M T Jelonek; S Khilko; B K al-Ramadi; Y S Kim; S E Maher; A L Bothwell; D H Margulies
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

3.  The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.

Authors:  Arunima Bandyopadhyay; Rebecca L Fine; Stacey Demento; Linda K Bockenstedt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2011-01-22       Impact factor: 12.479

4.  Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting.

Authors:  Tarek M Fahmy; Robert M Samstein; Casey C Harness; W Mark Saltzman
Journal:  Biomaterials       Date:  2005-04-18       Impact factor: 12.479

5.  Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus.

Authors:  Yen Cu; W Mark Saltzman
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

6.  Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer.

Authors:  H S Yoo; T G Park
Journal:  J Control Release       Date:  2001-01-29       Impact factor: 9.776

7.  Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6.

Authors:  Wenda Gao; Lorraine Thompson; Qiang Zhou; Prabhakar Putheti; Tarek M Fahmy; Terry B Strom; Su M Metcalfe
Journal:  Cell Cycle       Date:  2009-05-04       Impact factor: 4.534

Review 8.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

9.  Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.

Authors:  S H Gavett; X Chen; F Finkelman; M Wills-Karp
Journal:  Am J Respir Cell Mol Biol       Date:  1994-06       Impact factor: 6.914

10.  Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.

Authors:  G Horneff; G R Burmester; F Emmrich; J R Kalden
Journal:  Arthritis Rheum       Date:  1991-02
View more
  29 in total

Review 1.  Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market.

Authors:  Michele F Oliveira; Pedro P G Guimarães; Alinne D M Gomes; Diego Suárez; Rubén D Sinisterra
Journal:  J Chem Biol       Date:  2012-11-30

2.  An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response.

Authors:  Erin R Steenblock; Tarek Fadel; Michael Labowsky; Jordan S Pober; Tarek M Fahmy
Journal:  J Biol Chem       Date:  2011-08-17       Impact factor: 5.157

Review 3.  Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.

Authors:  Sean M Geary; Aliasger K Salem
Journal:  Crit Rev Oncog       Date:  2014

Review 4.  Nanoscale artificial antigen presenting cells for cancer immunotherapy.

Authors:  Kelly R Rhodes; Jordan J Green
Journal:  Mol Immunol       Date:  2018-03-07       Impact factor: 4.407

5.  Functional assessment of peptide-modified PLGA nanoparticles against oral biofilms in a murine model of periodontitis.

Authors:  Mohamed Y Mahmoud; Jill M Steinbach-Rankins; Donald R Demuth
Journal:  J Control Release       Date:  2019-01-25       Impact factor: 9.776

6.  iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.

Authors:  Lijun Ma; Qiubing Chen; Panpan Ma; Moon Kwon Han; Zhigang Xu; Yuejun Kang; Bo Xiao; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

Review 7.  Materials based tumor immunotherapy vaccines.

Authors:  Weiwei Aileen Li; David J Mooney
Journal:  Curr Opin Immunol       Date:  2013-01-18       Impact factor: 7.486

8.  Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk.

Authors:  Kartik Sehgal; Ragy Ragheb; Tarek M Fahmy; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  J Immunol       Date:  2014-07-30       Impact factor: 5.422

Review 9.  Size matters: gold nanoparticles in targeted cancer drug delivery.

Authors:  Erik C Dreaden; Lauren A Austin; Megan A Mackey; Mostafa A El-Sayed
Journal:  Ther Deliv       Date:  2012-04

10.  Induced clustered nanoconfinement of superparamagnetic iron oxide in biodegradable nanoparticles enhances transverse relaxivity for targeted theranostics.

Authors:  Ragy R T Ragheb; Dongin Kim; Arunima Bandyopadhyay; Halima Chahboune; Beyza Bulutoglu; Harib Ezaldein; Jason M Criscione; Tarek M Fahmy
Journal:  Magn Reson Med       Date:  2013-02-07       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.